The Epigenetically-Regulated microRNA-378a Targets TGF-β2 in TGF-β1-Treated Hepatic Stellate Cells

Cell Physiol Biochem. 2016;40(1-2):183-194. doi: 10.1159/000452536. Epub 2016 Nov 18.

Abstract

Background/aims: In liver fibrosis, the activation of hepatic stellate cells (HSCs) is considered as a pivotal event. It is well known that transforming growth factor-β1 (TGF-β1) is the main stimuli factor responsible for HSC activation. microRNAs (miRNAs), regulating various biological processes, have recently been shown to be involved in HSC activation. A recent study reported that deficiency of miR-378a contributes to cardiac fibrosis via TGF-β1-dependent paracrine mechanism. However, the involvement of miR-378a and its roles in TGF-β1-induced HSC activation remains largely unknown.

Methods: miR-378a expression was detected in TGF-β1-treated cells and patients with cirrhosis. Then, effects of miR-378a overexpression on cell proliferation and HSC activation were analyzed. We also analyzed the binding of miR-378a to the 3'-untranslated region of TGF-β2.

Results: In response to TGF-β1, miR-378a expression was down-regulated in a dose-dependent manner. miR-378a overexpression suppressed both cell proliferation and cell cycle in TGF-β1-treated LX-2 cells. Moreover, miR-378a overexpression inhibited TGF-β1-induced HSC activation including the reduction of α-smooth muscle actin (α-SMA) and type I collagen. Similarly, miR-378a resulted in a reduction in cell proliferation, and the expressions of α-SMA and Col1A1 in TGF-β1-treated primary HSCs. Notably, TGF-β2 was confirmed as a target of miR-378a by luciferase reporter assays. Interestingly, miR-378a promoter methylation may be responsible for miR-378a down-regulation in TGF-β1-treated LX-2 cells and TGF-β1-treated primary HSCs. Further studies confirmed that reduced miR-378a was associated with promoter methylation in patients with cirrhosis compared with healthy controls.

Conclusion: Our results demonstrate that miR-378a expression is associated with its methylation status in TGF-β1-treated cells, and epigenetically-regulated miR-378a inhibits TGF-β1-induced HSC activation, at least in part, via TGF-β2.

MeSH terms

  • 3' Untranslated Regions / genetics
  • Animals
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Azacitidine / pharmacology
  • Base Sequence
  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Proliferation / drug effects
  • Collagen Type I / metabolism
  • DNA (Cytosine-5-)-Methyltransferases / genetics
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Epigenesis, Genetic* / drug effects
  • Hepatic Stellate Cells / cytology
  • Hepatic Stellate Cells / drug effects
  • Hepatic Stellate Cells / metabolism*
  • Humans
  • Liver Cirrhosis / genetics
  • Liver Cirrhosis / pathology
  • Male
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Promoter Regions, Genetic / genetics
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta1 / pharmacology*
  • Transforming Growth Factor beta2 / genetics*
  • Transforming Growth Factor beta2 / metabolism

Substances

  • 3' Untranslated Regions
  • Collagen Type I
  • MIRN378 microRNA, human
  • MIRN378 microRNA, rat
  • MicroRNAs
  • Transforming Growth Factor beta1
  • Transforming Growth Factor beta2
  • DNA (Cytosine-5-)-Methyltransferases
  • Azacitidine